Audiences evaluating health technologies expect evidence that answers their specific questions. Regulators, assessors, payers and clinicians each apply different standards and need different answers.
Understanding what evidence a health technology needs requires mapping the full evidence portfolio across all of those audiences. Evidence plans are often created in silos, resulting in portfolio gaps that are discovered too late.
We work cross-functionally with your organisation to understand the full set of questions that need answering, identify evidence gaps, and build strategies that answer them.
Our team has worked across the full evidence lifecycle in global biopharma, biotech and medtech, spanning multiple therapeutic areas, with in-house creative and design capability.
Direct access to senior expertise and the ability to move at pace allow us to identify and close evidence gaps while there is still time, protecting value across the full product lifecycle.
1D
Stage 1
Discover
We establish the full decision landscape including what questions need answering, who is asking them, and which gaps in the current evidence base remain addressable. This applies equally to a programme that has not yet begun and one that is already underway but facing uncertainty.
2D
Stage 2
Design
Evidence portfolios grow as programmes develop. We connect every study, analysis and output to a specific decision and a specific audience. Where work is already underway, we assess its fit and design around it.
3D
Stage 3
Deliver
We ensure every output reaches the decision it was designed for, whether that means supporting study execution, providing operational oversight of real world evidence programmes, or building the infrastructure to sustain evidence generation over time.
